Unexpectedly, we found no statistical differences in prognosis between the NPM1-mutated AML cases with high VCAN expression and those with low VCAN expression, despite the fact that patients with high VCAN had a slight downward trend of survival time. The gene discussed is VCAN; the disease is acute myeloid leukemia.